<DOC>
	<DOCNO>NCT01894633</DOCNO>
	<brief_summary>Background purpose : Chloroquine ( CLQ ) , antimalarial drug , lysosomatrophic effect associate increase sensibility Radiation leakage hidroliticenzimes , increase apoptosis , autophagy mediate lysosomalhidrolases increase oxidative stress `` vitro '' . In phase II study evaluate efficacy safety radiosensitizing Chloroquine plus concomitant 30 Gray ( Gy ) Whole-brain irradiation ( WBI ) patient brain metastasis ( BM ) solid tumor .</brief_summary>
	<brief_title>Study Whole-brain Irradiation With Chloroquine Brain Metastases</brief_title>
	<detailed_description>Seventy-three eligible patient randomize . Thirty-nine patient receive WBI ( 30 Gy 10 fraction 2 week ) concomitant 150 mg CLQ 4 week ( CLQ group ) . Thirty-four patient receive schedule WBI concomitant placebo 4 week ( control arm ) . All patient evaluate quality life ( QoL ) use EORTC QLQ-C30 questionnaire ( Mexican version ) begin radiotherapy one month later .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>18 80 year age At leat one brain metastasis MRI KPS 70 RTOGRPA I II Basic Laboratory requirement Candidates radiosurgery , neurosurgery Patients treat radiotherapy enter study</criteria>
	<gender>All</gender>
	<minimum_age>46 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prophylactic Cranial Irradiation</keyword>
	<keyword>Metastasis</keyword>
	<keyword>Cloroquine</keyword>
</DOC>